“Pharma Clinical Trial Services Market and Industry forecast 2020-2030 set to grow to $150.15bn by 2030” says new Visiongain report

20 March 2020
Pharma

Visiongain has launched a new pharma report: Pharma Clinical Trial Services Market and Industry Forecast 2020-2030: Early Phase Services, Late Phase Services, Other Services, Pharma, Biotech, Other End-users, Cancer, Cardiovascular Diseases, CNS, Infectious Diseases, Metabolic Diseases, Other Disease.

This report encompasses the global market for pharmaceutical clinical trial services. It provides a comprehensive and critical analysis of the market, including the subsectors of early phase services and late phase services. The report also assesses the key therapeutic areas in which leading clinical research organizations (CROs) operate, namely, cancer, cardiovascular disease, CNS disease, infectious diseases and metabolic disease.

The lead analyst of the report commented "Biotech, pharmaceutical & medical device companies continue to develop at a fast pace owing to continuous expenditure on R&D, rising demand for biopharmaceuticals and increased healthcare needs for the geriatric population. In order to fulfil this, the demand for effective clinical trials has increased in order to ensure the effectiveness and safety of products. This demand is further propelled by the increasing importance of contract research organizations in emerging markets. The main challenges faced in this market are the lengthy authorisation, and approval procedures imposed by regulatory authorities."

Leading companies featured in the report include Quintiles, Laboratory Corporation of America (LabCorp), Pharmaceutical Product Development (PPD), Parexel International, ICON, INC Research Holdings, inVentiv Health & Other Companies

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain’s analysis indicates that total revenue on Tuberculosis Treatment Drugs Market will be $1,080 million in 2020 due to the World Health Organization strong commitment towards ending TB leading to increase in funding for the research and development both in developed as well and under-developed markets

Due to maturity of generic drug market, companies are moving away from generics drug into therapeutic market by building strong portfolio for development of anti-tuberculosis drug emphasizing all types of TB cases.

06 April 2020

Read

The Global Wound Care Market Is Set to Boom, Particularly in Emerging Economies

The global wound care market is big, and only set to grow bigger.  Currently, estimates show a CAGR of 4.6% in the years to come, with the overall market growing from US$19.8 billion in 2019 to US$24.8 billion by 2024.  The industry is ripe with opportunity, with that growth coming from several factors – but most especially growth in emerging …

30 March 2020

Read

“The global nasal drug delivery technology market is estimated to have reached $44,385 million in 2019” says new Visiongain report

Nasal Sprays segment held the largest market share of the global nasal drug delivery technology market in 2019.

30 March 2020

Read

“Global Stem Cell Technologies and Applications market set to grow to $10903.0m by 2025” says new Visiongain report

New technologies will be needed to ensure that scaling-up of manufacturing operations can be done effectively once stem cell treatments enter the market.

24 March 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever